Entera Bio Ltd. Reports Q2 2024 Financial Results and Notable Business Updates
Entera Bio Ltd. (NASDAQ: ENTX), a frontrunner in the development of orally delivered peptides and small therapeutic proteins, has recently released its financial results for the second quarter of 2024. Additionally, the company has achieved critical milestones in the development of its lead clinical compound, EB613, for the treatment of osteoporosis and low bone mineral density (BMD) in post-menopausal women. This article briefly summarizes Entera Bio’s financial performance, key business updates, and exciting advancements in its clinical programs.
Financial Performance
For the quarter ended June 30, 2024, Entera Bio reported a solid financial performance. This period showcased the company’s continued commitment to advancing its innovative oral peptide therapies. While specific revenue and expenditure figures were not disclosed, the company reaffirmed its strong financial position to support ongoing and future clinical trials.
Phase 2 Clinical Trial Data for EB613 Published
In an encouraging development, Entera Bio announced the publication of the Phase 2 clinical trial data for its oral PTH(1-34) peptide tablets (EB613) in the prestigious Journal of Bone and Mineral Research (JBMR) in April 2024. The Phase 2 trial investigated the efficacy of EB613 against a placebo in post-menopausal women with low BMD or osteoporosis. The results demonstrated that EB613 significantly improved BMD, bolstering its potential as a viable oral therapeutic option for osteoporosis. This publication not only validates Entera Bio’s scientific approach but also enhances the visibility and credibility of EB613 within the medical community.
Regulatory Progress for EB613
Another significant milestone was achieved in March 2024 when the American Society for Bone and Mineral Research (ASBMR) announced that the U.S. Food and Drug Administration (FDA) would rule on the qualification of treatment-related changes in BMD as a surrogate endpoint for fractures in future osteoporosis drug trials within the next 10 months. This ruling is part of the Study to Advance BMD as a Regulatory Endpoint (SABRE) project, where Entera Bio is a key participant. The anticipated FDA ruling is crucial for the Phase 3 program of EB613, as it would streamline the path to regulatory approval by enabling the use of BMD as a validated endpoint in clinical trials.
Conclusion
Entera Bio Ltd. has made substantial progress in both its financial stability and clinical development programs in the second quarter of 2024. The publication of Phase 2 trial data for EB613 and the impending FDA ruling on qualifying BMD as a surrogate endpoint accentuate the company’s advances in developing effective oral therapies for osteoporosis. Investors and stakeholders can look forward to further updates as Entera Bio continues to pioneer in the realm of oral peptide therapeutics.
Title
Entera Bio Ltd. Shines in Q2 2024 with Major Advances in Oral Osteoporosis Treatment
Comments